Intellectual Property Industries

Bar Admissions

  • New York
  • Ontario, Canada

Court Admissions

  • U.S. Court of Appeals for the Federal Circuit
  • U.S. District Court for the Eastern District of New York
  • U.S. District Court for the Southern District of New York

Education

  • J.D., University of Western Ontario, 2007
  • M.Sc., Chemistry (Organic), University of Toronto, 2004
  • B.Sc., Immunology, University of Toronto, 2002

Judicial Clerkships

  • Justice Roger T. Hughes, Federal Court of Canada
T +1 212.218.2579
F +1 212.218.2200
 

Christina Schwarz

Partner

Christina Schwarz is a pharmaceutical and biotechnology patent litigator whose practice focuses on complex litigation and contested proceedings before the Patent Trial and Appeal Board. In addition to her District Court experience, she has argued on behalf of major pharmaceutical companies at the United States Court of Appeals for the Federal Circuit and the Patent Trial and Appeal Board. Christina also frequently counsels clients of all sizes on litigation and non-litigation matters, and conducts pre-suit investigations. Her work covers a wide range of pharmaceutical and biotechnology products and technologies, including drugs or treatments for numerous different cancers and non-malignant tumors, immunosuppression, HCV, renal disease, Pompe disease, schizophrenia, drug formulations, drug delivery devices and polymers.

Representative Clients

  • Novartis
  • Genzyme
  • Gilead
  • Warner Chilcott

Significant Matters

  • Novartis v. Breckenridge, West-Ward and Par (Zortress® (everolimus) for kidney and liver transplants) (D. Del., Fed. Cir., PTAB-IPR)
  • Novartis v. West-Ward (Afinitor® (everolimus) for renal cell carcinoma and pancreatic neuroendocrine tumors) (D.Del., Fed. Cir., PTAB-IPR)
  • Novartis v. Par (Afinitor® (everolimus) for breast cancer) (D.Del.)
  • Novartis v. Breckenridge (Afinitor® (everolimus) for renal cell carcinoma, renal angiomyolipoma and tuberous sclerosis complex with subependymal giant cell astrocytoma) (D. Del., PTAB-IPR)
  • Novartis v. Mylan (Afinitor® Disperz (everolimus) for tuberous sclerosis complex with subependymal giant cell astrocytoma) (D. Del.)